With the legalization of marijuana fast approaching in July 2018 in Canada, as well as states across the U.S., there are many online resources, touting anything from the benefits of cannabis for cancer pain and nausea, to cannabis being the cure for cancer. What is the truth? What is based on scientific evidence? We believe, given our mandate and vast readership of patients, caregivers and health professionals, that we have a responsibility to take a lead and keep our readers up to date on the latest evidence-based resources, government guidelines, and current news, regarding purchasing and using medical marijuana for medical purposes so you can make informed decisions.
Please check back to this page often for updates and feel free to share it with your physician.
We’d like to hear from patients who have experience using medical marijuana to manage cancer treatment side-effects. Please email Karen Irwin if you’re interested in sharing your story.
The following steps outline the process to obtain cannabis for medical purposes from a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR).
Health Canada maintains an updated list of all licensed producers on its website. Health Canada does not authorize the operation of retail storefronts, such as “compassion clubs” or “dispensaries”.
To register with a licensed producer under the ACMPR, you need to follow the following steps:
Globe and Mail Articles
It’s expected that Shoppers, which is owned by grocer Loblaw Cos. Ltd., will sell both dried bud and cannabis-infused oils to medical patients on the internet. Canadian regulations restrict the sale of medical marijuana in storefronts and pharmacies. The drug is sold today on the web and delivered to patients through the mail.
With legalization on the horizon in Canada, dispensaries are marketing marijuana as a cure for what ails you – including cancer. Do the claims hold up? Adriana Barton takes a closer look at the science behind cancer and cannabis.
A new study conducted in a cancer center in a state with legalized medicinal and recreational marijuana found that approximately one-quarter of surveyed patients used marijuana in the past year, mostly for physical and psychological symptoms. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that legalization increased the likelihood for use among patients.
Still, treating metastatic cancer and its symptoms is serious business. In addition to undergoing photon radiation therapy, Newton-John says she has been using cannabis grown by her husband to help with the pain caused by her illness. Although it’s still a somewhat controversial topic in the U.S. (and illegal at the federal level), some experts believe medical cannabis really can help with chronic pain—especially pain that’s related to cancer.
Current Oncology Special Supplement Issue: Use of Cannabinoids in Cancer Care
This Current Oncology supplement brings together the work of some of the leading minds around the world who have dedicated themselves and their laboratories to understanding the role of cannabis and cannabinoids in the pathophysiology and management of cancer. This collection of papers takes us on a journey from bedside to bench and back, and provides a series of important sign-posts that will help to chart a path to better cancer care.
Following are the articles found in this supplement:
The treatment of cancer, including the disease itself and the symptoms associated with cancer and its therapy, is one of the most important emerging frontiers in cannabinoid therapeutics. With new regulatory environments opening up in Canada and around the world, access to a variety of quality-controlled cannabis-based products and administration techniques is becoming a reality for patients and their families desperate for new approaches to the devastating effects of cancer. The same is true for scientists and clinical researchers, who are starting to realize that, after years of deep freeze on cannabis-related research, funding, and materials, a thaw is starting. The promise, and even the hype, can reach hysterical proportions, with claims of cannabis cancer cures circulating in cyberspace at a furious pace. The challenge in the coming months and years will be to channel this interest into a productive clinical research program that informs and enlightens all those affected by cancer and its ravages.
Neuroblastoma (nbl) is one of the most common solid cancers in children. Prognosis in advanced nbl is still poor despite aggressive multimodality therapy. Furthermore, survivors experience severe long-term multi-organ sequelae. Hence, the identification of new therapeutic strategies is of utmost importance. Cannabinoids and their derivatives have been used for years in folk medicine and later in the field of palliative care. Recently, they were found to show pharmacologic activity in cancer, including cytostatic, apoptotic, and antiangiogenic effects.
The most studied and established roles for cannabinoid therapies include pain, chemotherapy-induced nausea and vomiting, and anorexia. Moreover, given their breadth of activity, cannabinoids could be used to concurrently optimize the management of multiple symptoms, thereby reducing overall polypharmacy. The use of cannabinoid therapies could be effective in improving quality of life and possibly modifying malignancy by virtue of direct effects and in improving compliance or adherence with disease-modulating treatments such as chemotherapy and radiation therapy.
Much attention has been paid to the unearthing of the 2500-year-old mummy known as the “Siberian Ice Maiden.” Discovered in 1993, her subterranean burial chamber included a pouch of cannabis among other archeologic findings1. Magnetic resonance imaging revealed that the princess had a primary tumour in the right breast, with axial adenopathy and metastatic disease. It is hypothesized that the cannabis was used to manage her pain and perhaps other symptoms, or even possibly as a treatment for her malignant disease.
Widely used as medicine during the ensuing millennia, cannabis disappeared from the pharmaceutical armamentarium in the 1940s as its prohibition took hold. Today, we are in the midst of what appears to be something of a medicinal cannabis renaissance, with patients across the globe gaining increased access to this potent botanical medicine. In a 2014 WebMD poll, 82% of oncologists indicated their belief that patients should have access to cannabis, ranking highest among medical subspecialists in their support2. Regrettably, most oncologists trained during the era of cannabis prohibition and have no knowledge of how to use the plant as medicine. In these days of targeted therapies and nanotechnology, the modern oncologist might feel somewhat ill at ease recommending a herbal intervention, notwithstanding the number of potent cytotoxic chemotherapeutic agents derived from plants.
I just learned that my ovarian cancer is back and that I need to start chemotherapy. At 5 feet, 7 inches, I weigh only 95 pounds, having lost 30 pounds since the surgery. I don’t want to lose any more weight. And so I research options to help with appetite. All recommended products have side effects I don’t like. The one exception is cannabis. I decide to ask my oncologist for a prescription.
In addition to the well-known palliative effects of cannabinoids on some cancer-associated symptoms, a large body of evidence shows that these molecules can decrease tumour growth in animal models of cancer. They do so by modulating key cell signalling pathways involved in the control of cancer cell proliferation and survival. In addition, cannabinoids inhibit angiogenesis and decrease metastasis in various tumour types in laboratory animals. In this review, we discuss the current understanding of cannabinoids as antitumour agents, focusing on recent discoveries about their molecular mechanisms of action, including resistance mechanisms and opportunities for their use in combination therapy. Those observations have already contributed to the foundation for the development of the first clinical studies that will analyze the safety and potential clinical benefit of cannabinoids as anticancer agents.
The opportunities to improve and expand palliative care are many. In this supplement, Current Oncology is presenting a discussion on cannabinoid therapeutics. I believe that, as a therapeutic class, cannabinoids have an important role to play in oncologic palliative care—a role that I predict will only grow with time, as knowledge and acceptance of these agents becomes mainstream once more, as in the 19th and early 20th century in North America and Europe.